IZB - Innovation and Start-up Center Biotechnology’s Post

Thrilled to share my latest contribution to ADRES Int'l Biotech Consultation & Execution's Biotech Standard Magazine! I dive deep into the unique attributes transforming Europe's biotech landscape, from centuries-old academic powerhouses to cutting-edge funding models reshaping our industry's future. In this piece, I explore five key drivers that make Europe's biotech ecosystem special, drawing from real-world examples like Immunos Therapeutics' inspiring journey from university spin-off to clinical-stage innovator. I'm curious to hear your thoughts: Which of these attributes will have the most significant impact on Europe's biotech future? Let's discuss this in the comments below! #Biotech #Innovation #EuropeanBiotech #Startup #LifeSciences

1. French biotech startup Generare has raised €5 million in seed funding to enhance drug discovery through cloning natural molecules produced by microorganisms. 2. The company aims to identify and repurpose these molecules for human treatments, drawing inspiration from historical drug discovery methods. 3. Generare's innovative approach involves cloning and biosynthetics to analyze genetic material rapidly, allowing for quicker identification of promising compounds. 4. Since launching its platform, the startup has discovered over 1,000 genetic recipes, including more than 100 novel chemical molecules with antibiotic properties. 5. The company emphasizes the efficiency of its technology, claiming a significantly faster process for transforming genetic recipes into usable molecules. 6. Generare's focus includes soil microorganisms and marine environments, recognizing the vast unexplored chemical diversity in nature. 7. The startup plans to scale its operations and engage in co-development of drugs with pharmaceutical partners while addressing antibiotic resistance issues in the industry. 8. Generare highlights the need for governmental support to create a viable business model for antibiotic development amid ongoing market challenges.

🔬 Avenue Biosciences raises $2.5M in seed funding to improve their protein engineering platform 👉 https://ain.social/4hkFsy1 Avenue Biosciences, a Helsinki-based biotech startup, has secured $2.5M in seed funding led by Voima Ventures, with support from Inventure and US angel investors! The company, founded in 2023 by Tero-Pekka Alastalo, Katja Rosti, and Juho Kellosalo, is on a mission to make life-saving therapies more accessible through innovative protein engineering technologies. Avenue’s machine learning platform optimizes signal peptides to improve protein delivery in cells, reducing development times and production costs for essential treatments like mRNA therapies and monoclonal antibodies. With this funding, Avenue Biosciences is poised to tackle bottlenecks in biotech, making complex therapies more affordable and scalable. The startup plans to launch commercial sales in Q4 and expand into Nordic and North American markets. #BiotechInnovation #SeedFunding #ProteinEngineering #LifeSciences #NordicStartups

Medytox has signed business agreements with Korean bio startups Mimetics and Exollence Biotechnology as part of the 2024 Seoul Biohub-Medytox Open Innovation Program. https://lnkd.in/gK64tZPu

Live from #ATW25, Kerstin Dolph discusses the launch of Charles River’s Incubator Program, designed to help early-stage developers overcome this translation hurdle, with scientific advisory services and capabilities to bolster programs from concept to cure. Explore the benefits: https://bit.ly/40tN4qi Learn more about the program: https://bit.ly/4apDxVO

🌟 Advanced Therapies Week Highlight: Launch of Charles River's Global Biotech Incubator Program 🌟 Join Kerstin Dolph, Senior VP of Manufacturing at Charles River Laboratories, and host Benjamin McLeod from Convey Bio for an exciting introduction to the Charles River Incubator Program (CIP). This pioneering program supports the journey of early-stage biotechnology companies in the development of advanced therapies. The CIP is dedicated to nurturing startups by offering regulatory guidance, quality expertise, personnel training, and access to laboratory facilities, all aimed at enhancing their path to commercial success. Discover how your biotech venture can apply and benefit from this unique opportunity to accelerate growth and innovation. #AdvancedTherapiesWeek #ATW25 #AdvancedTherapies #CharlesRiver #BiotechIncubator

Overall, more #money for German #biotechnology companies – but early financing remains difficult for startups from the sector. The complete analysis with numerous exciting results and insights: https://lnkd.in/ehzDUug8 #EYbiotech #BetterQuestions #BetterAnswers

Overall, more #money for German #biotechnology companies – but early financing remains difficult for startups from the sector. The complete analysis with numerous exciting results and insights: https://lnkd.in/dFvknKDW #EYbiotech #BetterQuestions #BetterAnswers

#fundingalert 💼Company: PolarityTE 💰Funding: $22.5Million ⚡Round: New Round 👥Investors: Institutional investors and current shareholders PolarityTE, headquartered in Salt Lake City, Utah, is a biotechnology company developing regenerative tissue products. It’s first regenerative tissue product is SkinTE®. PolarityTE has an open investigational new drug application (IND) for SkinTE® with the U.S. The credit agreement provides up to $10 million in total term loan capital including a first tranche of $5 million funded at closing. John Stetson, Jessica Shen, MD, MS, Arthur Telfeian Read more - https://lnkd.in/g7uH_rqU To share your startup story write us on - contact@startuprise.io #PolarityTE #biotechnology #biotechstartup #regenerativetissue #funding #fundingnews #news #startup #startupnews #startuprise

When the year started biotech investors had a smaller appetite for risk compared to previous years. Startups have needed to show a good business plan in addition to sound science to get funded. These were key takeaways from this year’s BIO CEO & Investor Conference that took place in New York on February 26. How is that playing out now in May? “There’s the science, and I love the science, but I have been forced to think about the business a lot more over the last two years,” Ellen Hukkelhoven, Head of Biotechnology Investments at Perceptive Advisors, told the conference. “The drug needs to work, it needs to get approved—which is a separate question—and then it needs to sell. Even in preclinical companies, we are thinking about all three of those stages when we invest.” While startups have come up with various strategies to stand out to investors, including offering a preview of their data to their top targets, nothing beats solid economic analysis. This is why we created our advanced PROVEN ™ platform — to help both investors and biotech innovators model uncertainty and predict the value of novel therapies with unprecedented flexibility and precision. #HEOR #DrugPricing #BioPharma #Innovation Link: https://lnkd.in/gW4YUd33